Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data
In this nationwide study persistence with CGRP-mAbs was excellent; dispensations of triptans and other preventatives decreased during CGRP-mAb therapy. Therapy breaks were common, but the majority resumed CGRP-mAbs, which indicates the need for long-term prophylaxis.
Authors
- Christian Wöber (ORCID: https://orcid.org/0000-0003-1382-1978)
- Berthold Reichardt (ORCID: https://orcid.org/0000-0002-1807-7482)
- Karin Zebenholzer (ORCID: https://orcid.org/0000-0001-6930-019X)
- Andreas Gleiß (ORCID: https://orcid.org/0000-0001-8010-7665)
- Walter Gall (ORCID: https://orcid.org/0000-0002-3020-3840)
Institutions
- Statistics Austria (AT)
- FWF Austrian Science Fund (AT)
- Comprehensive Cancer Center Vienna (AT)
- National Health Insurance Fund (RS)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/ene.70440
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47